Compugen（纳斯达克股票代码：CGEN）vs.Graphite Bio（纳斯达克代码：GRPH）财务调查

Compugen (NASDAQ:CGEN – Get Rating) and Graphite Bio (NASDAQ:GRPH – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Institutional & Insider Ownership

25.3% of Compugen shares are held by institutional investors. Comparatively, 52.5% of Graphite Bio shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 38.5% of Graphite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Compugen has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500. Comparatively, Graphite Bio has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Compugen and Graphite Bio, as provided by MarketBeat.com.

Compugen currently has a consensus price target of $4.50, indicating a potential upside of 663.36%. Graphite Bio has a consensus price target of $5.43, indicating a potential upside of 119.78%. Given Compugen's stronger consensus rating and higher possible upside, analysts clearly believe Compugen is more favorable than Graphite Bio.

Profitability

This table compares Compugen and Graphite Bio's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Compugen and Graphite Bio's gross revenue, earnings per share (EPS) and valuation.

Compugen has higher revenue and earnings than Graphite Bio. Compugen is trading at a lower price-to-earnings ratio than Graphite Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Compugen beats Graphite Bio on 7 of the 12 factors compared between the two stocks.

About Compugen

(Get Rating)

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

About Graphite Bio

(Get Rating)

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.